-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$37.67352.22% Upside
iTeos Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover iTeos Therapeutics, Inc.?
iTeos Therapeutics, Inc. has been rated by research analysts at Raymond James, Wells Fargo, H.C. Wainwright in the past 90 days.